A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Clinical trial NCT04512235 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04512235
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-03
- Primary completion
- 2025-04-08
- Enrollment
- 281
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.